

Cambodia Breast Cancer Initiative at the Sihanouk Hospital of HOPE

In Partnership with AstraZeneca and AmeriCares



Overview

- Partnership between AstraZeneca, AmeriCares, and Sihanouk Center of Hope (SHCH) Hospital in Phnom Penh, Cambodia
- The Cambodia Breast Cancer Initiative enables SHCH to strengthen existing treatment services while expanding in scale to reach additional patients
- We are currently in year 8, round 3 of the initiative which lasts from April 1st, 2014 – March 31st, 2018
- The staff at SHCH is composed of internationally trained and highly qualified physicians including surgeon specializing in Cancer surgery and pathologist trained in immunohistochemistry
- Breast cancer related mortality remains devastatingly high in the developing world due to limited awareness of self-screening practices, low access to diagnostic technology, and cost of oncology medicines
- AstraZeneca provides Arimidex free to both peri and post menopausal breast cancer patients in the Center of HOPE's treatment cohort
- Also work towards supporting the objective of educating Cambodian women about the importance of early detection and prompt care-seeking

Highlights

- Training conducted for peer educators on newly printed materials focused on breast awareness and early signs and symptoms which extends their outreach to the public
- Breast Cancer Program Coordinator role with primary focus is to enhance the Peer Educator program while making efforts to improve data collection and cross departmental coordination
- Efforts in Cambodia were so successful we expanded to the Philippines
 - 5 year program began in April 2011 allows Philippines General Hospital to extend Arimidex treatment to 10 indigent post menopausal women




Results/Impact Achieved

INDICATORS		YEAR 4	YEAR 5	YEAR 6	YEAR 7
		4-01-11 to 3-31-12	4-1-12 to 3-31-13	4-1-13 to 3-31-14	4-1-14 to 3-31-15
		YEAR END REPORT	YEAR END REPORT	YEAR END REPORT	YEAR END REPORT
NUMBER OF PATIENTS SCREENED AND ENROLLED IN PROGRAM					
A.	Existing patients (those continuing to receive follow-up treatment)	76	290	127	86
B.	New patients screened for breast cancer	257	434	620	808
C.	New patients diagnosed with breast cancer in this reporting period	51	95	82	78
D.	Total patients receiving treatment in this reporting period (A+C = existing + new)	127	385	208	164
PATIENT EDUCATION & OUTREACH					
R.	Number of individuals provided printed materials on early detection and	1800	5798	10454	11570
	Women educated by Peers	2347	1985	2715	7050
S.	Number of Peer Supporters Trained and Volunteering	5	5	12	12
T.	Number of Patient Educators Trained and Employed	3	3	1	2
	Additional Breast Cancer outreach volunteers trained	N/A	99	45	NA

* Product donations of AstraZeneca medicines also made for patient treatment

Challenges/Lessons Learned



Importance of early detection and treatment

Investing in public education will significantly improve breast cancer outcomes by enabling earlier detection and prompt treatment of breast cancer cases.



Need for a diversified treatment approach

Additional treatment alternatives needed for pre-menopausal, hormone receptor positive patients. Hospital also identified need for second-line therapeutic option for post-menopausal hormone receptor positive patients due to high number of advanced breast cancer cases.



Surgical Capacity Constraints

High demand for hospital's cancer related surgical services outweighs its implementing resources and capacity. Additional staffing, operating rooms, and inpatient beds hugely impacts the number of individuals able to be helped.